Most Low-Risk DTC Patients Do Not Achieve Recommended TSH Levels

Abstract

Get full access to this article

View all access options for this article.

References

Ringel

, Sosa

, Baloch

, et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid, 2025; 35(8):841–985; doi: 10.1177/10507256251363120.

Díez

, Anda

, Alcazar

, et al. Assessment of levothyroxine therapy adequacy in low-risk differentiated thyroid carcinoma: A multicenter cohort study. Front Endocrinol (Lausanne), 2025; 16:1652862; doi: 10.3389/fendo.2025.1652862.

Flynn

, Bonellie

, Jung

, et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab, 2010; 95(1):186–193; doi: 10.1210/jc.2009-1625.

Molewijk

, Fliers

, Dreijerink

, et al. Quality of life, daily functioning, and symptoms in hypothyroid patients on thyroid replacement therapy: A Dutch survey. J Clin Transl Endocrinol, 2024; 35:100330; doi: 10.1016/j.jcte.2024.100330.

Hoftijzer

, Heemstra

, Corssmit

EPM

, et al. Quality of life in cured patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab, 2008; 93(1):200–203; doi: 10.1210/jc.2007-1203.

Yavuz

, Yazan

, Hekimsoy

, et al. Assessment of attainment of recommended TSH levels and levothyroxine compliance in differentiated thyroid cancer patients. Clin Endocrinol (Oxf), 2022; 97(6):833–840; doi: 10.1111/cen.14787.

Gullo

, Latina

, Frasca

, et al. Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. PLoS One, 2011; 6(8):e22552; doi: 10.1371/journal.pone.0022552.

Wells

, Asa

, Dralle

, et al. 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid, 2015; 25:567–610; doi: 10.1089/thy.2014.0335.